Pharma Stocks
-
Astellas Pharma (TSE:4503) Stock Valuation After KRAS Trial Progress And AI Overhaul
Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply…
Read More » -
Pharma, tech, EVs cheer FY27 budget as tobacco, steel count the cost
The proposed national budget for FY2026–27 has set the stage for a sweeping transformation of the country’s capital market, with…
Read More » -
NewAmsterdam Pharma (NAMS) Stock Valuation After New Obicetrapib Phase 3 And PREVAIL Trial Updates
Clinical data on obicetrapib puts NewAmsterdam Pharma in focus NewAmsterdam Pharma (NasdaqGM:NAMS) has drawn fresh attention after reporting Phase 3…
Read More » -
Teva’s Biosimilar Boom Is Just Getting Started. Is It Time to Buy This Rebounding Pharma Stock?
Teva Pharmaceutical Industries (TEVA +0.20%) has clawed back from the brink like few drugmakers have. After a long stretch of…
Read More » -
Is Zasocitinib’s Phase 3 Beat And New Shelf Filing Altering The Investment Case For Takeda Pharmaceutical (TSE:4502)?
Earlier this month, Takeda Pharmaceutical announced that its oral TYK2 inhibitor zasocitinib delivered statistically superior Phase 3 results versus deucravacitinib…
Read More » -
Chugai Pharmaceutical (TSE:4519) Stock Valuation After Recent Share Price Weakness
Chugai Pharmaceutical (TSE:4519) has drawn fresh attention after recent share price moves, with the stock down about 4.5% over the…
Read More » -
Is BioCryst Pharmaceuticals, Inc. (BCRX) A Good Stock To Buy Now?
Is BCRX a good stock to buy? We came across a bullish thesis on BioCryst Pharmaceuticals, Inc. on BioEquity Watch’s Substack. In…
Read More » -
Pharma and Biotech M&A Boom Accelerates as Companies Expand Pipelines – June 11, 2026
Key Takeaways Johnson & Johnson will buy Firefly Bio for $1B, adding a platform targeting KRAS-driven cancers Lilly struck multiple…
Read More » -
Crinetics Pharmaceuticals (CRNX) is One of the Best AI Driven Biotech Stocks, Here is Why
When Jeff Bezos said that one breakthrough technology would shape Amazon’s destiny, even Wall Street’s biggest analysts were caught off…
Read More » -
Is It Too Late To Reassess Ligand Pharmaceuticals (LGND) After A 115% One-Year Rally?
If you are wondering whether Ligand Pharmaceuticals at US$248.24 still offers value after a strong run, the next sections will…
Read More »